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ABSTRACT 
Intestinal ischemia is a clinical gastrointestinal emergency associated with high 
morbidity and mortality.  Aim of this study was to investigate whether activation of µ 
opioid receptors (µORs) protects from the injury induced by intestinal ischemia and 
reperfusion.  Ischemia was induced by occlusion of the superior mesenteric artery (45 
min) and followed by reperfusion (5hours) (I/R).  Sham Operated (SO) and normal (N) 
mice served as controls.  Each group received subcutaneously: (1) saline solution; (2) 
the µOR selective agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) (0.01 
mg kg−1); (3) DAMGO and the selective µOR antagonist [H-D-Phe-Cys-Tyr-D-Trp-
Arg-Thr-Pen-Thr-NH2] (CTAP) (0.1 mg kg−1) or (4) CTAP alone.  Compared to SO, 
I/R induced intestinal inflammation as indicated by the histological damage and the 
significant increase in myeloperoxidase (MPO) activity (index of tissue neutrophil 
accumulation).  Treatment with DAMGO significantly reduced tissue damage and MPO 
activity in I/R and these effects were reversed by CTAP.  Significant increase in levels 
of the inflammatory cytokine TNF-and IL-10mRNA was detected in I/R mice 
compared to SO.  DAMGO significantly reduced TNF- mRNA levels in I/R, effect 
that was abolished by CTAP, but did not modify IL-10 mRNA levels.  µOR mRNA 
levels were comparable in I/R, SO and N mice.  There was a significant delay in 
gastrointestinal transit in both I/R and SO compared to N mice, which was not affected 
by DAMGO administration.  In summary, this investigation shows that exogenous 
activation of ORs plays a protective role in our experimental model of mesenteric I/R 
in mice.  Indeed, OR activation is able to reduce the intestinal damage induced by I/R, 
through a mechanism that appears to be in part mediated by TNF-.  
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1. INTESTINAL ISCHEMIA AND REPERFUSION 
1a. PATHOGENESIS AND PHYSIOLOGY 
Intestinal ischemia and reperfusion injury could occur in several clinical situations 
such abdominal surgery, small bowel transplantation, cardiopulmonary bypass, 
strangulated hernias and neonatal necrotizing enterocolitis.
1
  Intestinal ischemia is a real 
gastrointestinal emergency, characterized by high morbidity and a mortality rate ranging 
from 60% to 80%, depending from the source of obstruction
2
.  During this pathology 
the three arteries usually compromised by obstruction are the celiac trunk, the superior 
mesenteric artery (SMA) and the inferior mesenteric artery (IMA).  Recently, the 
American Gastroenterology Association (AGA) classified this severe abdominal event 
into three major categories, focusing on clinical features: 
1. Acute mesenteric ischemia: further subdivided into major arterial occlusion, minor 
arterial occlusion, major embolus, mesenteric venous thrombosis or splanchnic 
vasoconstriction (non-occlusive mesenteric ischemia) based on the etiology of the 
occlusion. 
2. Chronic ischemia: consequence of longstanding atherosclerotic diseases and also 
known as intestinal angina. 
3. Ischemic colitis: correlated to colonic ischemia.3, 4 
Patients which develop acute embolic ischemia often have history of cardiac 
diseases, like atrial fibrillation and ventricular aneurysm.  Thrombotic ischemia could 
be consequence of both venous and arterial thrombosis and is usually related to a 
history of atherosclerotic disease and chronic abdominal pain.  In the non-occlusive 
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patients no vascular occlusion is usually demonstrated because blood flow is present in 
larger arteries, but ischemia is consequence of persistent vasospasm correlated to severe 
cardiac failure, sepsis, vasoconstriction induced by renin, angiotensin, vasopressin, 
thromboxanes and leukotrienes or administration of -adrenergic agents and 
medications (i.e. digitalis)
2
. 
The most common cause of chronic ischemia is atherosclerotic occlusion or severe 
stenosis of mesenteric arteries.  Slow-growing obstruction into the vessel brings to a 
gradual reduction in blood flow to the intestine and since collateral circulation is present 
the patient may be asymptomatic even with stenosis of several arteries.  Chronic 
mesenteric ischemia usually causes abdominal pain and weight loss.
3
 
Ischemic colitis represents the consequences of acute or, more commonly, chronic 
blockage of blood flow through arteries that supply the large intestine.  Patients 
experience abdominal pain, usually, localized to the left side of the abdomen, along with 
tenderness and bloody diarrhea.  Severe ischemia may lead to bowel necrosis and 
perforation, which results in an acute abdomen and shock, frequently, being 
accompanied by lactic acidosis
5
. 
During the ischemic insult interruption of blood supply leads to poor organ 
oxygenation which rapidly damage metabolically active tissues.  Even a short period of 
ischemia can impair mucosal functions, whereas a severe and longer ischemia can cause 
transmural necrosis of the bowel wall with perforation and peritonitis. 
At the cellular levels, ischemia causes mitochondrial dysfunction by blocking aerobic 
energetic metabolism.  The depletion of intracellular levels of adenosine triphosphate 
(ATP) alters cellular homeostasis generating loss of ion transfer regulation, intracellular 
acidosis, changes in membrane permeability and fluidity which leads to intracellular 
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accumulation of ions accompanied by an influx of water and swelling of cells
6
.  
Endothelial cells lose their anti-adhesive properties and develop thrombogenic and 
adhesive surface.  In the main time, progressive accumulation of toxic metabolites, 
diminished production of bioactive agents (e.g. nitric oxide, prostacyclines) and release 
of degradative enzymes lead to cell death and tissue necrosis.
7
 
During reperfusion, restoration of blood flow and reintroduction of oxygen in the 
ischemic tissue initiate a cascade of events that may exacerbate cell injury (oxygen 
paradox) and this reperfusion damage is frequently more severe than the initial ischemic 
insult.  The renewed presence of oxygen leads to oxidative stress with formation of 
cytotoxic reactive oxygen species (ROS), release of pro-inflammatory substances and 
activation and adhesion of polymorphonuclear neutrophils (PMNs).  This adhesion of 
leukocytes to the endothelial surface and consequent activation impairs endothelial cell 
layer integrity and allows leakage of proteins and macromolecules into extra-vascular 
space producing tissue edema.  Moreover, activated neutrophils, endothelium, 
monocytes and platelets release ROS and a variety of inflammatory cytokines, such as 
tumor necrosis factor  (TNF-), platelet activating factor (PAF) and leukotrienes 
generating a sort of vicious circle which enhances exponentially the inflammatory 
response. 
Potentially every organ can be subject to I/R damage, however, the intestine is one of 
the internal organ most sensible to I/R injury because enterocytes and endothelial cells 
are labile and particularly susceptible to damaging effects of both hypoxia (ischemia) 
and re-oxygenation (reperfusion).
1
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1b. MEDIATORS INVOLVED IN I/R INJURY 
Intestinal ischemia-reperfusion injury is consequence of a complex cascade of events 
correlated to imbalance between oxygen consumption and supply, production of 
cytotoxic and reactive molecules and onset of acute inflammatory reaction.  A multitude 
of mediators play a role in the development of I/R tissue damage, the mains are listed 
below. 
Xanthine Oxidase and Reactive Oxygen Species 
Reactive Oxygen Species (ROS) are extremely reactive and unstable free radicals 
(molecules which have a single unpaired electron in their orbit) originating when O2 is 
reintroduced in the ischemic tissue during the reperfusion period.  ROS can be involved 
in reaction with organic and inorganic chemical substances including proteins, lipids, 
carbohydrates and particularly cell membranes and nucleic acids generating severe 
cellular damage.
7
 
During the ischemic period ATP is catabolized to adenosine and then to 
hypoxanthine.  Under physiological condition hypoxanthine is converted to xanthine by 
Xanthine Dehydrogenase (XDH).  During ischemia the depletion of ATP creates loss of 
ATP-dependent ion channel regulation which results in passive ions shift across cell 
membranes: K
+
 and Mg
2+
 diffuse out, but Na
+
, Ca
2+
 and H2O diffuse in, causing cell 
swelling.
1
  Accumulation of intracellular Ca
2+
 enhances conversion of XDH to Xanthine 
Oxidase (XO), with degree of conversion proportional to the length of ischemic period.  
During reperfusion O2 reintroduced into the tissue reacts with hypoxanthine and XO to 
produce the superoxide anion (●O2
-).  This kind of oxygen free radical, under 
physiological conditions, is transformed into hydrogen peroxide (H2O2) by the action of 
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the enzyme Superoxide Dismutase (SOD) and its damaging effects are prevented.  
However, during reperfusion of ischemic tissue, these natural defenses may be 
overcome.  Moreover, in presence of iron (Fe
3+
), H2O2 and ●O2
-
 undergo the Haber-
Weiss reaction and produce hydroxyl radical (●OH) which is more reactive and 
cytotoxic than the relatively low-energy radical ●O2
-. 
 
Fe
3+
   +   ●O2-  Fe
2+
   +   O2 
Fe
2+
   +   H2O2  Fe
3+
   +   OH
-
   +   ●OH 
 
●OH is able to react with the fatty acid side chain of the membrane phospholipids 
generating lipid peroxides, that are themselves free radicals.  Consequence of this lipid 
peroxidation is a severe damage at organelles and cell membranes, with loss of 
selectivity in ionic exchange and release of hydrolytic enzymes and cytotoxic products 
responsible for cell necrosis and apoptosis.
7
  ROS and substances released from the 
cells are also able to attract and promote the adherence of granulocytes to the 
microvascular endothelium.  
Haber-Weiss reaction 
Figure 1: Schematic mechanism of cellular injury induced by Reactive Oxygen Species (ROS) during I/R.  
During ischemia ATP intracellular store are depleted while hypoxanthine is accumulated.  During 
reperfusion O2 react with Xanthine Oxidase (XO), Superoxide Dismutase (SOD) and iron generating ROS. 
cellular membrane 
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Polymorphonuclear Neutrophils (PMNs) 
Occlusion and reperfusion of an artery triggers a vigorous immune response. Acute 
ischemia causes activation of the endothelium with increased permeability and 
expression of adhesion molecules.  Moreover the increased release of bioactive 
substances from the endothelial cells augments the recruitment and the infiltration of 
circulating leukocytes into the post-ischemic tissue.  Following I/R injury, 
polymorphonuclear neutrophils (PMNs) have been shown to be the major leukocytes 
found in necrotic tissue, particularly in postcapillary venules
8
. 
The process of migration of PMNs from the postcapillary venules to the area of 
inflammation is complex and highly coordinated.  It can be subdivided in three phases: 
1. Rolling: PMNs roll along the endothelium surface. This event is mediated by 
interaction between endothelial adhesion molecules (like P-selectine and E-
selectine) and L-selectine which are constitutively expressed on leukocytes.  
During I/R on the endothelial cells there is an increased expression and/or avidity 
of these adhesion molecules. 
2. Adhesion: rolling along the endothelial cell surface brings PMNs into close 
proximity to chemoattractants (like leukotriene B4, C5a, Interleukine-8 and PAF) 
and chemokines.  Interaction of these molecules with leukocyte receptors activates 
2-integrins (CD11a, CD11b, and CD11c/CD18) which strongly bind intracellular 
adhesion molecules (ICAM-1) and platelet/endothelial cell adhesion molecules 
(PECAM-1) present on endothelial vascular cells. 
3. Extravasation: the interaction between PMNs and endothelial cells allow the 
extravasation of the leukocyte out of the blood vessel and into the interstitial 
space.
1
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Figure 1: Process of migration of polymorphonuclear neutrophils from the venules to the area of 
inflammation.  Mechanism of activation: rolling, adhesion and extravasation. (Reproduced from Mallick 
et al., Dig Dis Sci 2004) 
Active PMNs after adhesion and migration through the endothelium generate local 
damage through release of a burst of free radicals, proteolytic enzymes (collagenase, 
elastase, and cathepsin) and peroxidase (myeloperoxidase).  While XO appears to 
account for the initial oxidant stress elicited in venules after a few minutes of 
reperfusion, activated PMNs appear related to the greater oxidant stress that occurs 
thereafter.  Neutrophils activation and infiltration increases the vascular permeability 
triggering endothelial barrier dysfunctions.  Moreover PMNs can cause tissue injury by 
physically impairing microcirculation and thereby increasing the extension of the 
ischemic area. 
Summarizing, activated neutrophils contribute to intestinal ischemia-reperfusion 
injury through multiple mechanisms: release of free radicals and proteolytic enzymes as 
well as stimulation of cytokine release from local cells; thus promoting further 
neutrophil recruitment and plugging of capillaries.  
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Nitric oxide 
Nitric oxide (NO) is a ubiquitous biological messenger involved in many 
physiological and pathophysiological events.  NO is a free radical highly reactive 
synthesized via oxidation of the guanidinic group of L-arginine by a family of NO 
synthase enzymes (NOS), which three isoforms have been identified and cloned: 
endothelial (eNOS), neuronal (nNOS) and inducible (iNOS)
9
.  NO produced by 
constitutively expressed eNOS contributes mainly to the regulation of blood pressure, 
organ blood flow distribution and platelets aggregation.  NO produced by nNOS has an 
important role as neurotransmitter both in the brain and in the gastrointestinal tract.  
iNOS expression is induced only in response to cytokines, growth factors and 
endotoxins produced by a variety of cells (e.g. smooth muscle cells and macrophages)
10
. 
NO plays a double role in intestinal I/R, either protective or toxic.  Under normal 
condition NO, produced in small amount, has various important physiological roles like, 
for instance, to reduce arteriolar tone via guanylate cyclase activation in smooth muscle, 
to inhibit platelet aggregation, to minimize adhesive interactions between leukocytes 
and mesenteric endothelium surface and to prevent formation of substances that activate 
NF-kB.  Another important role of NO is to scavenge the intracellular levels of ROS; 
particularly it reacts with the superoxide anion (●O2
-
) producing peroxynitrite (ONO2
-
): a 
molecule that is not itself a free radical, but is a powerful oxidant that can cause 
pronounced lipid peroxidation when present in relevant concentration. 
Under physiological conditions the flux of NO largely exceeds the ●O2
-
 production, 
and NO is able to exert its benefic effects on intestine tissue, however, during I/R, NO 
could be involved in the production of cytotoxic molecules.  During the early phase of 
reperfusion there is an accumulation of ●O2
-
 and an augmented production of NO 
10 
 
through activation of iNOS.  These concomitant events enable almost all the NO 
produced reacts with the huge amount of ●O2
- 
present, leaving little or no bioactive NO 
available to maintain optimal tissue blood flow and to minimize interaction between 
endothelial cells, platelets and immune cells (particularly PMNs).  Loss of endogenous 
NO has disastrous consequences resulting in severe dysfunction of the endothelium and 
the presence of ONO2
-
 implies augment of the already strong oxidative stress, thus 
contributing to exacerbate the I/R injury. 
 
  
Figure 2: Schematic mechanism of cellular injury induced by NO derivates during I/R.  NO reacts 
with radical oxygen species, generated during reperfusion, producing peroxynitrite (ONO2
-
) which 
induces peroxidation of membrane phospholipids. 
cellular membrane 
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Nuclear Factor k-light-chain-enhancer of activated B cells (NF-κB) 
NF-κB is a specific nuclear transcription factor which regulates the expression of 
pro-inflammatory genes and appears to perform an important function in generation and 
resolution of I/R injury. 
NF-κB is activated in the intestine by inflammatory stimuli (e.g. PAF and leukotriene 
B4), cytokines (e.g. TNF-, Il-1), LPS and oxidants, and the activation of this 
transcription factor leads to expression of various genes, codifying different proteins 
involved in the amplification and maintenance of the inflammatory response. 
NF-κB is a member of dimeric transcription factor complex families. Into cytoplasm 
of unstimulated cells, it is normally found in its inactive form (p50/p65/I-κB ternary 
complex).  The complex formed by NF-κB and IκB coordinates the activation of a 
series of genes codifying for cytokines and adhesion molecules associated to I/R events.  
Stimulation of cell by vast number of agents, including cytokines (such TNF-α and IL-
1β) free radicals, oxidants or inflammatory mediators results in phosphorylation and 
ubiquitination of the I-κB inhibitory subunit, which then undergoes to proteasome 
degradation.  The active complex p50/p65 is now able to translocate into the nucleus 
and to activate transcription of its target genes, which are diverse and include those 
involved in the inflammatory response, cell adhesion and growth control.  Indeed, NF-
κB induces expression of a variety of pro-inflammatory proteins such as adhesion 
molecules (ICAM-1, VCAM-1, P- & E-selectine), tumor necrosis factor (TNF-, -), 
interleukins (IL-1, IL-6), chemokines and inducible enzymes (iNOS, COX-2)
11
. 
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During the reperfusion period, re-oxygenation appears to be the key stimulus for 
activation of the I-κB kinase (IKK) responsible for the phosphorilation of the inhibitory 
subunit and consequent activation of NF-κB.12  Inflammatory response elicited by I/R 
occurs several hours after the beginning of reperfusion due to this transcription-
dependent synthesis of pro-inflammatory proteins. 
Activation of the NF-κB family of transcription factor has been demonstrated in 
various models of experimental I/R, including intestinal I/R.  In vivo studies on mice 
lacking IKK, investigated the role of NF-κB in controlling I/R injury and showed that 
inhibition of NF-κB activation in enterocytes prevents the increase in systemic TNF-α 
concentration after I/R and consequently reduces systemic inflammatory response.  In 
the main time, inhibition of NF-κB activation also resulted in severe apoptotic damage 
Figure 4: Mechanism of NF-κB action. In an inactivated state, NF-κB is located in the cytosol 
complexed with the inhibitory protein I-κBα. A variety of extracellular signals can activate the 
enzyme IκB kinase (IKK), which phosphorylates the IκBα protein, which results in ubiquitination and 
dissociation of IκBα from NF-κB. The activated NF-κB is then translocated into the nucleus and 
begins the transcription of genes codifying pro-inflammatory proteins.  (modified from Wikipedia) 
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to the reperfused intestinal mucosa, suggesting a dual function of NF-κB system, 
responsible for both tissue protection and systemic inflammation
13
. 
 
Cytokine cascade 
The inflammatory cascade triggered by I/R events results in the secretion of multiple 
pro-inflammatory and counter-regulatory cytokines that play a pivotal role in I/R 
induced destruction of intestinal mucosa, tissue injury, systemic toxicity and lethality. 
Among the whole set of cytokines, previous studies performed in rodents have 
shown the involvement of TNF-IL-1 and IL-10 in modulating intestinal I/R 
damage.  During I/R insult, TNF-α is amply released from macrophages, monocytes, 
lymphocytes and mast cells and elicits leukocyte migration, fever and acute-phase of the 
inflammatory response.  This pro-inflammatory cytokine plays an essential role in 
enhancing neutrophil influx, tissue injury and lethality in experimental models of I/R.  
Indeed, treatment of rats with anti-TNF- antibodies prevented neutrophil influx and 
tissue injury after intestinal I/R
14
 and treatment of mice with a soluble chimeric form of 
the TNF-α receptor reduced lethality correlated with greater and earlier TNF-α increase 
in serum
15
. 
Interleukin 1 (IL-1) is a cytokine released from macrophages and other antigen-
presenting cells, which promotes the inflammatory response by increasing endothelial 
leukocyte adhesion and phagocyte activation.  IL-1 has also been shown to activate the 
IL-8 gene thereby increasing the neutrophil population at the site of inflammation. 
Serum levels of interleukin 1 significantly increase after I/R16 and play a pivotal role in 
the systemic inflammatory response syndrome (SIRS), which can lead to sepsis and 
multisystem organ failure if not corrected
17
. 
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Several studies have now demonstrated that IL-10 modulates pro-inflammatory 
cytokine production and tissue injury following ischemia and reperfusion injury.  IL-10 
normally serves to down-regulate the inflammatory response, but its role in I/R injury is 
controversial.  Indeed, studies in IL-10 deficient mice suggested that endogenous IL-10 
exerted anti-inflammatory role during reperfusion injury, possibly by regulating early 
stress genetic response (c-Jun kinase activation), neutrophil influx and cytokine 
production
18
.  Exogenous administration of IL-10 also reduced the systemic 
inflammatory response in a rodent model of intestinal reperfusion injury, an effect 
associated with inhibition of cytokine production and neutrophil accumulation
19
.  Other 
studies on mice demonstrated that this anti-inflammatory cytokine does not play a 
significant local or systemic protective role in I/R injury
20
, or even that IL-10 may 
increase the tissue damage after intestinal I/R
21
.  These contrasting effects could be 
referred to different involvement of this cytokine during the time-course of reperfusion 
phase; anyhow further studies are required to clarify the role of IL-10 in I/R damage. 
  
15 
 
Complement 
The complement system is part of the immune system and consists of a number of 
small proteins found in the blood, normally circulating as inactive zymogens.  When 
stimulated by one of several triggers, proteases in the system cleave specific proteins to 
release cytokines and initiate an amplifying cascade of further cleavages.  The result of 
this activation cascade is a massive amplification of the immune response and activation 
of the cell-killing membrane attack complex. 
Several studies showed that activation of complement system is responsible for I/R 
injury of the intestine.
1
  In fact, reperfusion is able to activate the complement cascade 
leading to widespread deposition of complement fragments on the microvasculature. 
These complement activation products are chemotactic for leukocytes and neutrophils, 
elicit oxidant formation and are also able to induce expression of adhesion molecules 
genes (e.g. ICAM-1) and up-regulation of pro-inflammatory cytokines (TNF-, IL-
1INF-).  Moreover, activation of complement system can lead to translocation into 
the nuclei of NF-κB and consequent increased transcription of a variety of pro-
inflammatory proteins and enzymes (e.g. iNOS, interleukins, adhesion molecules)
22
. 
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T-cells and B-cells 
It is well established that the innate immune system, such as complement, PMNs, 
cytokines and macrophages participate in ischemia reperfusion injury.  Recent evidence 
showed that also lymphocytes and cell-mediated immunity play an important role in 
pathophysiology of I/R damage
8
. 
Indeed, studies on mice with severe combined immunodeficiency (SCID), lacking 
both T and B cells, gave evidence that intestinal I/R-induced leakage of albumin is 
associated with the recruitment of CD4+ and CD8+ T-cells.  Moreover, T-cells seem to 
modulate the recruitment of neutrophils that occurs hours after reperfusion, and this 
effect could account for the increased endothelial permeability that occurs within 
minutes after reperfusion rather than direct cytotoxic actions of the T-cells themselves
23
.  
Although most evidence has linked lymphocytes with the early I/R injury, emerging 
data associate these cells with healing from ischemic damage:CD4
+
CD25
+
 T regulatory 
cells reduce the pro-inflammatory sequel of I/R by altering the chemokine and 
chemokine-receptor expression
24
. 
While the role of T cells can be either pathogenic or protective depending on timing 
of the injury and type of T-cells, the role of B cells has been found to be predominantly 
pathogenic
25
. 
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Neurotransmitters, autacoids and enzymes 
A variety of neurotransmitters, autacoids and enzymes locally released could perform 
an important function in the pathogenesis of intestinal I/R injury.  In the last years our 
group analyzed the involvement of different bioactive substances in an experimental 
model of mesenteric I/R in rodents. 
Intestinal ischemia followed by 24 hours of reperfusion in rats increased the 
expression of the inhibitory transmitter vasoactive intestinal polypeptide (VIP) and, in 
the main time, reduced the expression of the excitatory transmitter substance P (SP).  
Observation that changes in these transmitter expression in I/R rats were prevented by 
pre-treatment with a NOS inhibitor [N-nitro-L-arginine, L-NAME], or a N-methyl-D-
aspartate receptor (NMDA-R) antagonist [(+)-5-methyl-10,11-dihydro-5HT-[a,b] 
cyclohepten-5,10-imine, MK-801], suggests an involvement of the glutamatergic 
system and its interaction with nitric oxide in intestinal ischemia/reperfusion.  We 
propose that glutamate released locally in response to I/R activates the NMDA-Rs thus 
triggering a sustained influx of Ca
2+
 into neurons leading to NOS activation and NO 
production and adaptive changes in enteric transmitters that might contribute to 
gastrointestinal dysmotility and local inflammatory responses induced by I/R
26
. 
Serotonin (5-HT) is an important neurohumoral transmitter widely distributed at both 
central and peripheral level (80% of total body 5-HT is found in the gut, predominantly 
within the granules of mucosal enteroendocrine cells).  Previous study on rats showed 
an increase in the plasmatic levels of serotonin after mesenteric I/R, probably due to an 
increase in the release of 5-HT by the injured intestine
27
.  Different findings support 
either negative or protective role for 5-HT in intestinal I/R conditions, depending on 
18 
 
which receptor subtypes are activated.  Through administration of selective agonist 
[DOI: (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)] or antagonist [ketanserin] of 
the 5-HT2A receptor subtype, we investigated the role of this receptor in the functional 
alterations and inflammatory response caused by mesenteric I/R in mice.  We showed 
that inhibition of 5-HT2A receptors protects against mesenteric I/R injury, preventing 
gastrointestinal transit delay as well as tissue edema and leukocytes infiltration
28
. 
Reperfusion of ischemic tissue results in increased production of oxidants and 
radicals that in turn cause mast cells activation and degranulation, release of enzymes 
and bioactive amines (e.g. histamine)
29
.  Such event has been recognized as promoter of 
inflammatory cells infiltration, increased vasal permeability and mucosal dysfunction 
induced by mesenteric I/R but, so far, there is no clear indication about the protective or 
deleterious effect played by histamine (H) during episodes of intestinal hypoxia and re-
oxygenation.  We assessed the effects evoked by different histamine receptor (HR) 
subtypes on motor disorders and inflammation induced by I/R in mice, through the 
administration of selective histamine receptor blockers [H1R: mepyramine, H2R: 
famotidine, H3R: M85 or H3R/H4R: thioperamide].  Beneficial effects of selective 
histamine H2 and H4 receptors blockade were observed: famotidine prevented I/R-
induced colonic transit delay, while thioperamide (a mixed H3R/H4R antagonist), unlike 
the selective H3R antagonist M85, reduced leukocytes infiltration in ischemic mice. 
In the gut, mast cells are often in close vicinity to visceral afferents that express 
Proteinase-Activated Receptor 2 (PAR2)
30
.  We showed that PAR2 activation has a 
protective role in post-ischemic reperfusion induced injury in the intestine: in fact, 
intraduodenal administration of the selective PAR2 agonist SLIGRL-NH2 reduced 
19 
 
mucosal damage and accelerate gastrointestinal transit in I/R animals.  The 
inflammation caused by I/R might induce degranulation of mast cells with release of 
proteases, which activates PAR2 directly and/or through activation of visceral afferents.  
The mechanism underlying the protective effects of PAR2 activation appears to be 
mediated by mast cells degranulation and sensory afferents, because it was not observed 
in rats pretreated with cromolyn (a mast cell stabilizer) and chronic capsaicin (which 
ablates visceral afferents), with a mechanism that involves at least in part substance P 
release
31
. 
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1c. SYSTEMIC CONSEQUENCES OF INTESTINAL I/R 
Localized mesenteric ischemia/reperfusion event can trigger more severe systemic 
disorders associated to a high morbidity and a mortality rate which ranges from 60% to 
100%
3
.  In fact, damage to the microcirculation leads, locally, to irreversible intestinal 
necrosis, and disseminated intravascular coagulation (DIC) or systemic inflammatory 
syndrome (SIRS) in the whole body or in remote organs. 
During intestinal I/R, activated neutrophils infiltrate through endothelial cells, 
increasing vascular permeability and causing sub-mucosal and mucosal damage.  This 
increase in permeability often lead to translocation of enteric bacteria and bacterial 
products (e.g. LPS) from the gastrointestinal tract to extra-intestinal sites like lymph 
nodes, spleen and liver.  Subsequently bacteria are able to disseminate to the entire 
body, causing sepsis, shock or even multiple organ failure (MOF) and death.  MOF is 
characterized by dysfunction of immune system and activation of the coagulation 
cascade resulting in thrombosis, disseminated intravascular coagulation and immune-
failure. 
After I/R insult, production and release of pro-inflammatory cytokines and radical 
substances, such as superoxide anion or hydrogen peroxide, can lead to severe systemic 
consequences.  In fact, mediators released into circulation during reperfusion are able to 
activate endothelial cells in any distant organs and to enhance expression of adhesion 
molecules and interaction between neutrophils and endothelial cells in different vascular 
beds.  The most frequent damage is pulmonary edema associated with accumulation of 
neutrophils-rich alveolar fluids which can lead to respiratory failure and acute 
respiratory distress syndrome (ARDS)
32
.  Other remote organ injuries often following 
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intestinal I/R events include systemic inflammatory response syndrome (SIRS), cardiac 
dysfunction, renal failure and hepatic injury. 
Another systemic consequence of intestinal I/R can be the insurgence of alteration in 
absorptive functions of the small intestine, which can lead to deficient absorption of 
nutrients, often associated with an increased mortality
33
. 
 
 
Figure 5: Systemic consequences of local Ischemia/Reperfusion injury.  Schematic illustration of the 
mechanism involved in the development of remote organ dysfunction.  (modified from Carden D.L., 
Granger D.N., J Pathol 2000) 
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1d. THERAPEUTIC APPROACHES TO I/R INJURY 
Several potential therapeutic approaches have been proposed for treatment of 
ischemia/reperfusion injury, and a variety of different drugs and therapeutic strategies 
have shown protective effects in experimental animal model of intestinal I/R injury.  
Among the strategies which have been successfully used, the most noteworthy are: 
 
 Ischemic preconditioning 
 Antioxidants administration 
 Anti-complement therapy 
 Anti-leukocyte therapy 
 Hypothermia 
 iNOS inhibition 
 
Ischemic preconditioning (IPC) consists in exposure of the intestinal tissue to one or 
more brief period of ischemia, which is demonstrated to protect from the damaging 
effects of a subsequent prolonged ischemic event.  This protective effect of IPC was 
first described on canine heart by Murry and colleagues in 1986
34
, and subsequently 
demonstrated also in intestinal tissue by Hotter in 1996
35
.  IPC is able to prevent 
leukocyte activation and adhesion, capillary plugging and extra-vascular leaking of 
proteins, preserving, in this way, endothelial functions of arteries, capillaries and 
venules and diminishing morphological lesions in the entire intestinal tissue. 
IPC protective effects can be distinguished in two different phases: (1) early or 
classic preconditioning and (2) late preconditioning.  Early IPC occurs within minutes 
after the initial transient ischemic insult and the beneficial effect last at least 2-3 hours.  
This early phase involves direct modulation of specific cell functions (e.g. stimulation 
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of phospholipase C, activation of protein kinase C) and is protein synthesis-
independent.  The acute protection afforded by early IPC is lost if the interval of time 
that elapses between the transient and the prolonged ischemia exceeds the 2-3 hours.  
However, a delayed protective response appears again if the prolonged ischemia occurs 
12-24 hours after the initial vascular occlusion and lasts for about 3-4 days.  This late 
preconditioning phase involves the activation of multiple stress response genes and 
requires de novo synthesis of various proteins, including antioxidant enzymes, NO 
synthase and heat shock proteins. 
Several hypothesis have been proposed to explain these events, but the exact 
mechanism through which IPC exerts its protective role is still unclear.  In the gut IPC 
is associated to an increased mucosal activity of the antioxidant enzymes superoxido-
dismutase (SOD), catalase and glutathione peroxidase (GSH)
36
 and to augmented NO 
production.  Thus, IPC appears to enhance target tissue‟s antioxidant status, improving 
the innate resistance to a second ischemic insult.  Evidences showed that in the small 
intestine, IPC seems to prevent post-ischemic leukocyte adhesion by maintaining the 
bioavailability of nitric oxide (a potent endogenous anti-adhesive agent) and preventing 
the expression of adhesive molecules by endothelial cells (P-selectin)
37
.  In addition, 
IPC is able to decrease the systemic translocation of bacteria from the intestine
38
. 
Since opioid peptide have been detected in the gut and their receptors were also 
found to be widely expressed in the small intestine, the role of endogenous opioid 
peptide in the protective effect of IPC on intestinal ischemic injury has been 
investigated.  Studies on experimental model of intestinal I/R in rats showed that 
pretreatment with morphine, an opioid receptor agonist, could produce a 
preconditioning-like protection against damage caused by a subsequent I/R; whereas 
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pretreatment with the opioid receptor antagonist naloxone significantly blocked both 
IPC- and morphine-induced protection.  Moreover, evidence that the release of the 
endogenous opioid peptide Leu-enkephalin was markedly increased during IPC, 
suggests that endogenous opioid peptide may mediate the protective effects of intestinal 
IPC and may also be an endogenous protective substance in the rat small intestine
39
. 
 
Antioxidants are molecules provided of free radical scavenging properties, which are 
helpful in reducing damage induced by the oxidative burst occurring during I/R.  A 
variety of molecules have been successfully used in experimental model of ischemia, 
including xantine-oxidase inhibitor (e.g. allopurinol), Superoxide Dismutase, iron 
chelator, N-acetyl cysteine, ethanol, ascorbic acid, tocopherol, pentoxifylline, captopril 
and verapamil
1
. 
 
Anti-complement therapy consists in complement inhibition or depletion through 
administration of complement (C5a) receptor antagonist or anti-murine C5 monoclonal 
antibody.  This therapeutic approach has been shown to protect against intestinal I/R 
injury in rodents, attenuating intestinal mucosal injury and decreasing neutrophil 
infiltration
22, 40
. 
 
Anti-leukocytes therapy aims to prevent or attenuate the intestinal I/R damage 
mediated by immune cells.  Three different strategies have been tested in this field: (1) 
inhibition of leukocyte activation, by administration of antagonists of pro-inflammatory 
mediators which attract and activate leukocytes during I/R (e.g. TNF- antagonists14, 
LT-B4 antagonist
41
); (2) inhibition of leukocyte adhesion molecule synthesis through 
inhibition of nuclear transcription factors regulating genes codifying for adhesion 
proteins (e.g. NF-κB inhibitor12); (3) limitation of leukocyte-endothelial adhesion using 
25 
 
monoclonal antibody directed against adhesion molecules and preventing PMNs rolling 
and adherence on endothelial vascular cells
42
. 
 
Intestinal hypothermia, experimentally induced in rats by keeping tissue temperature 
around 15-20°C, is able to protect the intestinal mucosa from mesenteric I/R injury 
acting, probably, with a multi-factorial mechanism.  Indeed, hypothermia reduces 
consumption of oxygen and ATP, neutrophil infiltration, lipidic peroxidation and 
production of pro-inflammatory cytokines.  In addition, hypothermia also prevents NF-
κB activation and modulates expression of the oxidative stress protein iNOS in response 
to mesenteric I/R
43
. 
 
As previously described, NO plays a double role in pathophysiology of intestinal I/R.  
Supplementation of NO, achieved through treatment with NO precursor or donors, has 
been shown to ameliorate local and systemic I/R injury when administered before the 
ischemic event.  On the contrary, the reduction of NO tissue levels, gained through the 
selective inhibition of the iNOS isoform during the post-ischemic period, protects 
intestine from both motor disturbance and inflammatory response induced by 
mesenteric I/R in mice
44
. 
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2.  OPIOID RECEPTOR 
 
2a. OPIOID RECEPTORS 
Opiate derivatives like morphine and other alkaloids have been used in medicine for 
their analgesic properties from ancient times.  The word opium itself is derived from the 
Greek name for juice, the drug being obtained from the juice of the poppy Papaver 
Somniferum.  Opium contains more than 20 alkaloids (e.g. morphine, codeine, 
papaverine) characterized by different pharmacological properties. 
The existence of opioid receptors, through which opiates exert their action, was first 
proposed in 1954 by Beckett and Casy
45
 based on their studies of structure-activity 
relationships for antinociceptive activity in a series of synthetic opiates
45
.  Portoghese 
and colleagues first suggested in 1965 the existence of more than one opioid receptor 
type or the possible occurrence of multiple modes of interaction of ligands with opioid 
receptors
46
.  In 1975 Hughes and Kosterlitz isolated from cerebral tissue two 
pentapeptides sharing a similar pharmacological profile of morphine thus strengthening 
the idea of the existence of specific receptor targets.  The first definitive evidence that 
these opioid receptors did not form an homogeneous population was presented by 
Martin and colleagues in 1976
47
.  They proposed that there were three types of opioid 
receptors based on the pharmacological actions of different opiates in chronic spinal 
dogs, and named them μ („mu‟ for morphine), κ („kappa‟ for ketocyclazocine),  
(„sigma‟ for SKF 10047 or N-allynormetazocine).  Few years after, Lord and colleagues 
identified a high affinity receptor for opioid receptor ligands in mouse vas deferens and 
named it δ („delta‟ for vas deferens)48. 
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The amino acid sequences of all these receptor have been cloned and the 
recombinant receptors shown to have binding and functional characteristics consistent 
with their endogenous counterparts
49
.  There is about 60% of homology between these 
receptors and each one has seven trans-membrane domains characteristic of the G-
protein coupled receptor (GPCR) family. 
 
Figure 6: Amino acid sequence identity among the three cloned opioid receptor.  Amino acid residues of 
OR conserved in both - and -receptor, in either - or -receptor and in neither - nor -receptor are 
shown by black, gray and white circles, respectively. Branched structures show the potential N-linked 
glycosylation sites. [Minami M. and Satoh M. Neurosci Res 1995] 
 
Opioid receptors are associated to Gi/0 and their activation inhibits adenyl cyclase 
and Ca
2+
 channels, while opens K
+
 channels, generating changes in membrane 
polarization and inhibition of neurotransmitters release. 
Once presence of specific receptors for opiate alkaloid and related synthetic drugs 
was confirmed, the investigation for endogenous ligands for these receptors began and 
led to discovery of opioid peptides: Leu-enkephalin and Met-enkephalins
50, 51, β-
endorphin
51, 52
, and dynorphins
53
.  Opioid receptors have specific pharmacological 
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profile and a certain degree of selectivity for different endogenous ligands.  For 
instance, endorphins bind to - and -receptors with similar affinity, whereas 
dynorphine displays some selectivity for -receptor and enkephalins are the preferred 
ligands for -OR, but also have remarkable affinity for -OR54.  The recently 
discovered opioid peptides, endomorphine-1 and endomorphine-2, have several 
thousand-fold preference for OR over - and -receptor. 
Table 1: Endogenous opioid peptides selectivity among opioid receptors and their amino acid sequences. 
Opioid peptide Receptors Amino acids sequence 
Met-enkephalin  Tyr-Gly-Gly-Phe-Met 
Leu-enkephalin  Tyr-Gly-Gly-Phe-Leu 
-endorphin  
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-
Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-
Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
Dynorphin A (1-17) 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys-Trp-Asp-Asn-Gln 
Endomorphin-1  Tyr-Pro-Trp-Phe-NH2 
Endomorphin-2  Tyr-Pro-Phe-Phe-NH2 
 
Endogenous opioids are generating from three different genes, the pro-
opiomelanocortin (POMC), pro-enkephalin (PENK) and pro-Dynorphin genes, which 
give rise to several biologically active peptides, including -endorphin, enkephalin and 
dynorphin, whereas, the genes producing endomorphins have not been yet identified.  
These genes and their products have a broad distribution in the central and peripheral 
nervous system as well as into other organs and tissues, including the gastrointestinal 
tract
55
. 
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2b.  OPIOID RECEPTOR 
The μ opioid receptor subtype was originally defined and characterized 
pharmacologically on the basis of its high affinity for, and sensitivity to, morphine
56
.  
The endogenous opioids β-endorphin, [Met5]-enkephalin, [Leu5]-enkephalin, extended 
forms of [Met
5
]-enkephalin and truncated forms of dynorphin (e.g. dynorphin-(1-9) and 
shorter dynorphin peptides), have affinities for μ receptors which are consistent with a 
possible role for each of these peptides as natural ligands for this receptor type, although 
these endogenous mediators are not selective for μ receptors.  Recently discovered, 
endomorphin-1 and -2 appear to mediate their effects exclusively through the μ opioid 
receptor, although no gene, precursor protein, or other mechanism for their endogenous 
synthesis has been identified. 
Opiates used clinically preferentially activated OR even though their ligand 
selectivity profiles are impaired when they accumulate at high concentration, in which 
conditions they can interact with other opioid receptor subtypes
57
.  OR exogenous 
ligands can be subdivided in two groups based on their molecular structure: peptides 
(obtained modifying the endogenous opioid amino acid sequences) or non-peptides 
(gained modeling the opium alkaloids structures). 
Among the selective exogenous agonists for  opioid 
receptor, most known are morphine, fentanyl, sufentanyl, 
methadone, DAMGO and dermorphin; while selective 
antagonist are CTAP, CTOP, naloxonazine, MET-CAMO [5-
beta-methyl-14-beta- (p-nitrocinnamoylamino) -7,8-dihydro 
morphinone] and its corresponding N-cyclopropylmethyl analog (N-CPM-MET-
CAMO). 
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 opioid receptor AGONIST
Peptides
DAMGO Tyr-D-AIa-Gly-MePhe-Gly-oI
FK 33-824 Tyr-D-Ala-GIy-MePhe-Met(O)-oI
PLO17 Tyr-Pro-t-MePhe-D-Pro-NH2
Dermorphin Tyr-D-AIa-Phe-GIy-Tyr-Pro-Ser-NH2
Morphiceptin Tyr-Pro-Phe-Pro-NH2
Non- peptides
Sufentanyl Fentanyl
Methadone
CH3CH2OC N NCH2CH2CH3CH2CO N
C6H5
NCH2CH2
H3COH2C S
N
O
 opioid receptor ANTAGONIST
Peptides
CTOP D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2
CTP D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
CTAP D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2
TCTOP D-Tio-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2
Non- peptides
Naloxonazine N-CPM-MET-CAMO
MET-CAMO  
O
N
CH2CH
NHO
CH2
OH
N
O
N
CH2CH
OH
CH2
HO
O
N
H2
C
OHO
NHCOCH C
H
NO2
CH3
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ORs are members of seven transmembrane G-protein-coupled receptors super 
family and are able to activate different signal transduction systems.  These receptors 
can interact with five different Gi/0 proteins (Gi/1-2-3, G0/A-B) and are functionally coupled 
to several effectors pathways, including inhibition of adenyl cyclase and cAMP 
formation, increase of K
+
 currents, inhibition of Ca
2+ 
channels, modulation of inositol 
triphosphate (IP3) turnover and activation of mitogen-activated protein kinases 
(MAPK)
58
.  ORs can also interact with pertussis toxin-insensitive G proteins like Gz or 
G14-16, which respectively inhibit cAMP production and activate phospholipase C 
(PLC).  Moreover, the G complex is able to activate other various signaling pathways 
itself, generating different responses sometimes going in opposite direction compared to 
Gi/0 effects.  However, the G-correlated transduction system seems to be consequence 
of chronic activation of OR by agonists, while Gi/response results prevalently after 
acute stimuli.  Coupling of the OR to these effector systems attenuates neuronal 
activity by inhibiting neurotransmitters release and changing neuronal excitability by 
means of pre- and post-synaptic mechanisms. 
After ligand-receptor interaction, the OR undergoes adaptation such as de-
sensitization, down-regulation and re-sensitization in response to agonist treatment.  
These events regulate cellular responsiveness to receptor activation and result from 
receptor mediated processes including phosphorylation, endocytosis, intracellular 
sorting and recycling
59
.  Indeed, immuno-histochemical studies showed that OR 
undergoes rapid ligand-induced receptor internalization in both the soma and neuronal 
processes which persists for 4-6 hours; and that after appropriate intracellular sorting, 
requiring endosomal acidification, OR recycles to the cell surface in about 6 hours54. 
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Figure 7: Different transduction systems activated by OR.  This receptor can be coupled with different 
G subunits, and also G complex can stimulate various signal pathways.  AC = adenyl cyclase, STAT-3 = 
Signal Transducer and Activator of Transcription-3, PLC = Phospholypase C, MAPK = Mitogen Activated Protein 
Kinase, PI3K = Phosphoinositide 3-Kinase, GRK = G-Protein-coupled Protein Kinase, JNK = c-Jun N-terminal 
Kinase, RGS = Regulator of G-Protein Signaling Protein.  [modified from Clementi F. UTET, 2004
60
]. 
 
Pharmacological studies performed with selective agonists and antagonists, 
suggested the presence of multiple  opioid receptors subtypes referred to as 1 and 2 
and 3
61
: 
 1-ORs are expressed in the brain and are characterized by their high affinity for 
naloxonazine and several opioid ligands (including morphine and DALDE). 1-ORs and 
are involved in various opioid effects such as supraspinal analgesia, prolactin release, 
decrease in acetylcholine turnover and induction of catalepsy
62
. 
 2-ORs are expressed in the brain as well as in the gastrointestinal and 
respiratory tract; they have lower affinity for morphine and DALDE and appear to be 
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involved in respiratory depression, decreased dopamine turnover and delayed GI transit 
induced by opiates
54
. 
 ORs are localized on human peripheral monocytes and in invertebrate 
immunocytes, they have been characterized by binding assays as opiate alkaloid 
selective (e.g. morphine) and opioid peptide (e.g. Met-, Leu-enkephalin) insensitive.  
3–ORs are coupled to constitutive nitric oxide synthase-derived NO release and are 
involved with neural, immune, vascular and gut processes
63
. 
 
Table 2: Features of human  opioid receptors subtypes. 
 
  
 
OR OR OR
Tissue 
distribution 
Brain 
Brain, Spinal cord 
Gastrointestinal tract 
Respiratory tract 
Monocots, 
granulocytes, vascular 
endothelial cells, 
nervous tissue 
Signal 
transduction 
Decrease: 
Ca
2+
 and K
+
 channels 
cAMP 
Decrease: 
Ca
2+
 and K
+
 channels 
cAMP 
Increase: 
Ca
2+
 and constitutive 
NO release 
34 
 
Localization and functions 
In situ hybridization studies using highly selective probes for mRNA of the various 
opioid receptor subtypes have revealed that μORs are distributed throughout the 
neuraxis.  Into the Central Nervous System (CNS) the highest μ receptor densities are 
found in periaqueductal gray substance, spinal trigeminal nucleus, cuneate and gracile 
nuclei, and thalamus regions of the brain involved in pain perception
64
.  μORs mRNA is 
present also in nuclei involved in control of respiration (solitary tract, ambiguous and 
parabrachial), in areas processing memory, emotional reactions and behavior 
(amygdale, neocortex, nucleus accumbens), and in neurons of the area postrema able to 
induce nausea and vomiting
65
.  The μORs are also present in the superficial layers of the 
dorsal horn of spinal cord (dorsal root ganglia) and peripheral nerve terminals
66
. 
Activation of  opioid receptor by endogenous opioid peptides and opiate drugs 
modulate a variety of physiological functions and biological processes, including 
analgesia, stress response, immunity, motor activity and autonomic functions acting 
centrally as well as peripherally
67
. 
 Stimulation of central OR induces analgesia, by reducing both physical and 
psychic pain, produces drowsiness, apathy and sedation and also acts like a “mood 
controller” triggering euphoria and tranquility and, at the same time, minimizing anxiety 
and anguish.  Moreover, OR activation within the CNS generates severe respiratory 
depression, by reducing responsiveness of brainstem respiratory centre to carbon 
dioxide; miosis, body temperature adaptation and is able to control feeding stimuli, 
inducing anorexia, nausea and vomiting acting on chemoreceptor trigger zone for 
emesis, in the area postrema of the medulla. 
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 Consequences of peripheral activation of OR include inhibition of 
gastrointestinal transit and motility, due to increase of smooth muscle basal tone, 
enhance of non-propulsive contractions and marked decrease of propulsive contractions. 
OR are able to modulate gastrointestinal functionality since they trigger a decrease in 
gastric, biliary, pancreatic and intestinal secretions.  Alteration of various hormones 
secretion is another consequence of OR activation: increased release of prolactin 
(PRL) and growth hormone (GH), inhibition of luteinizing hormone (LH) release and 
urinary retention correlated to an increased release of antidiuretic hormone (ADH) are 
detected.  Furthermore, OR activation produces peripheral vasodilatation, reduces 
peripheral resistance and heart rate and inhibits baroreceptor reflex causing orthostatic 
hypotension.  Morphine and some opioids also release histamine from mast cells 
causing a rapid decrease of blood pressure and emerging of itch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 opioid 
receptor 
activation 
Figure 8: Endogenous opioids and pharmacologically 
administered opiate analogues bind and active ORs, 
which exert their effects in multiple central and 
peripheral target cells producing respiratory 
depression, analgesia, negative inotropic effect, 
immune-suppression, GI function alteration. [modified 
from Molina PE, J Intern Med 2006] 
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2c. OR IN THE GASTROINTESTINAL TRACT 
The enteric nervous system (ENS) represents the largest collection of neurons 
outside the CNS.  Enteric neurons originating from the myenteric and submucosal 
plexuses supply all layers of the gastrointestinal wall and exert essential roles in 
controlling bowel movement and transmucosal fluid exchange.  Due to these features 
ENS is able to regulate every aspect of digestion processes
68, 69
.  These neurons are able 
to synthesize and release acetylcholine (Ach), substance P, nitric oxide (NO), adenosine 
triphosphate(ATP), vasoactive intestinal polypeptide (VIP), 5-hydroxy-tryptamine 
(5HT) and also opioid peptides (b-endorphin, enkephalin, endomorphin)
70
.  Unlike other 
nervous system in the body, the ENS can work without central input from the brain and 
is often considered “the brain in the gut”. 
 opioid receptor has been localized in enteric neurons of various animal species and 
their relative distribution varies with gastrointestinal layer and region.  In the rat OR 
has been observed in neurons of both the submucosal and myenteric plexus and in fibers 
distributed to the muscle layers, mucosa, blood vessels, lymphatic nodes and to putative 
interstitial cells of Cajal in the myenteric and deep muscular plexus
71
.  By contrast, in 
guinea-pig, OR is localized predominantly to neurons of the myenteric plexus, which 
are more abundant in the small intestine, particularly the ileum, than in the stomach and 
proximal and to fibers distributed to the interconnecting strands and smooth muscle 
layer, where they form a dense network in the deep muscular plexus
71
.  In human gut, 
OR is present in specific regions of the small and large intestine: distribution and 
density are comparable in the human jejunum and colon. OR immunoreactivity is 
localized in neuronal cell bodies in both submucosal and myenteric ganglia and to nerve 
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fibers in the myenteric plexus, but not to the mucosa. OR are present on mononuclear 
cells in the lamina propria and on neutrophils in the microcirculation
72
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The OR immunoreactivity distribution in the gastrointestinal tract closely matches 
the distribution of the opioid peptides enkephalins
73
, and these molecules are likely to 
be the endogenous opioids that primarily activate neuronal OR in the gut, even though 
they are not selective for this opioid receptor type
55
. 
OR expressing myenteric neurons comprise functionally distinct types of neurons: 
including cholinergic and tachykinergic excitatory motoneurons ascending to the 
Figure 9: OR distribution in human gut specimens.  OR immunoreactivity is found in (A and C) 
myenteric neurons, (B and D) submucosal neurons, and (E and F) mucosal immune cells.  Arrows 
point to OR in neurons of the myenteric plexus of (A) the colon and (C) the jejunum, of the 
submucosal plexus of (B) the colon and (D) the jejunum, and in (E and F) immune cells.  MP, 
myenteric plexus; SMP, submucosal plexus. Calibration bars: 50 m. [Sternini C. et al. Neurogastroenterol 
Motil 2004] 
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muscle
54
 and ascending interneurons
74
.  In addition, OR expressing enteric neurons 
comprise a large proportion of descending neurons and cholinergic descending 
interneurons. 
Due to this widespread distribution activation by agonist of OR receptor can 
interrupt both excitatory and inhibitory neural inputs to GI muscles
75
.  The consequent 
motor effects are complex because, depending on whether interruption of excitatory or 
inhibitory neural pathways prevails, muscle relaxation or spasm will be observed.  As a 
result, μOR agonists inhibit gastric emptying, increase pyloric muscle tone, induce 
pyloric and duodenal-jejunal phasic pressure activity, delay transit through the small 
and large intestine, and elevate the resting anal sphincter pressure
75
.  The halt in 
propulsive motility combines with inhibition of gastrointestinal ion and fluid transport.  
Through prolonged contact of the intestinal contents with the mucosa and interruption 
of pro-secretory enteric reflexes, OR activation attenuate the secretion of electrolytes 
and water and facilitate the net absorption of fluid, resulting in a pronounced 
constipation
76
. 
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2d. OR AND IMMUNE RESPONSE 
Opioid receptor activation occurs as a natural response to injury resulting from 
increased release of opioid peptides in response to injury, infection, trauma and surgery.  
Although the most frequently associated effect of opioid is analgesia, several lines of 
evidence suggest that endogenous and pharmacological activation of opioid receptors 
affects immune function and can regulate immune response
77
. 
It is proved that immune cells recruited in inflamed tissue, such as T and B 
lymphocytes, granulocytes, monocytes and macrophages, contain all subtype of opioid 
peptides (endorphin, enkephalin, dynorphin and endomorphism).  Pro-opiomelanocortin 
(POMC) -related opioid peptides have been found in leukocytes of many vertebrates 
and invertebrates
78
, while pro-enkephalin (PENK)-related have been detected in human 
and rodent T and B cells, strongly indicating that opioid peptides derive from the same 
precursors both in nervous and immune system
79
.  Furthermore, -endorphin is present 
in secretory granules of macrophages and leukocytes, arranged at the cell periphery, 
ready for exocytosis
80
.  Indeed, leukocytes are capable of directly processing and 
releasing POMC- and PENK-derived peptides when subject to various stressful stimuli 
or in response to releasing agents such as viruses, corticotropin-releasing hormone 
(CRH), cytokines (e.g. IL-1), chemokines (e.g. CXCL1, CXCL2), and catecholamines 
(e.g. noradrenalin). 
Opiate mediated immune effects result from either direct interaction with OR on 
cells of the immune system
81
 or indirectly, through the activation of opioid receptors 
within the central nervous system and the resulting modulation of hypothalamic-
pituitary-adrenal axis and the sympathetic nervous system
82
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The locally produced opioid peptides can bind to OR located on macrophages, 
lymphocytes and mast cells, and exert various immunomodulatory effects including 
reduced expression and release of adhesion molecules, tumor necrosis factor (TNF), 
substance P and calcitonin gene-related peptide (CGRP)
67
.  Reports from in vivo and in 
vitro studies indicate that OR stimulation exerts suppression of multiple components 
of the host immune defense response including natural killer cell activity
83
, neutrophil 
complement and immunoglobulin receptor expression
84
, chemokine-induced 
chemotaxis
85
 and phagocytosis
86
.  Opioid peptide can also produce immunosuppressive 
effects on T cells including inhibition of cytotoxic T-cell activity, modulation of T-cell 
antigen expression, and depression of responses to T-cell mitogens. 
  
Figure 10: Opioid mediated immunomodulation and immunosuppression. L, lymphocytes, M, 
macrophages; MC, mast cells; ICAM; intercellular adhesion molecule; ROS, reactive oxygen species; -EN, 
-endorphin; Met-EK, Met-enkephalin. [modified from Molina PE, J Intern Med 2006] 
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OR and inflammatory response 
Besides the classical therapeutic properties of opioid drugs, the demonstration of 
opioid peptides and  opioid receptors expression by cells involved in the inflammatory 
reaction has lead to a new investigation focused on the roles of OR ligands in the 
regulation and modulation of tissue inflammatory responses
87, 88
. 
Inflammation of peripheral tissues leads to increased synthesis and axonal transport 
of opioid receptors in dorsal root ganglion neurons, resulting in their up-regulation in 
the peripheral nerve terminals
89
.  Furthermore, opioid peptides, present in many 
leukocyte subpopulation including lymphocytes, monocytes and granulocytes in the 
peripheral blood, in inflamed and non-inflamed lymph node and also immune cells 
which extravasate in the site of experimentally induced or clinical inflammation.  In 
early inflammation granulocytes are the major source of opioid peptide production; later 
in the inflammatory process, monocytes and macrophages are the predominant supply 
of these peptides
90
. 
Recent evidence suggests that OR could play a pivotal role in regulating intestinal 
inflammation.  It is proved that intestinal inflammation experimentally induced by 
intragastric administration of croton oil in mice, enhanced the potency of OR agonists 
in inhibiting gastrointestinal transit and secretion
91, 92
.  Moreover, gut inflammation 
significantly increased the levels of OR mRNA and receptor-protein located in the 
myenteric plexus suggesting that the enhanced effects of opioid observed in functional 
studies could be explained by an increase in the local synthesis and expression of the 
OR93.  Furthermore, in transparietal ileal and colonic samples of human patients 
suffering of inflammatory bowel diseases (IBD), compared to healthy intestine, a 6-30-
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fold increased expression of OR was observed94; supporting the hypothesis that up-
regulation of OR may operate a beneficial effect on abnormally accelerated intestinal 
transit and on the severity and duration of the inflammatory process. 
Philippe and colleagues showed that subcutaneous administration of selective 
peripheral MOR agonists significantly reduces inflammation in two experimental 
models of colitis, and this effect was abolished by concomitant administration of an 
opioid antagonist
95
.  Evidence of a genetic role for OR in the control of gut 
inflammation was provided by showing that OR-deficient mice were highly 
susceptible to colon inflammation.  The anti-inflammatory effects of OR in the colon 
appear to be mediated through the regulation of cytokine production and T cell 
proliferation
95
. 
Taken together, these evidences support the hypothesis that OR plays a role in the 
control of gut inflammation and suggest that OR selective agonist, able to act 
peripherally without central untoward side effects such as depression of breathing, 
clouding of consciousness, or addiction, might be new therapeutic molecules for the 
treatment of inflammatory bowel disease. 
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AIM OF THE STUDY 
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Considering recent evidences showing the involvement of  opioid receptor in 
controlling and regulating the intestinal inflammation, we hypothesized that ORs 
stimulation might attenuate the inflammatory response as well as the mucosal injury 
induced by intestinal ischemia and reperfusion events.  Aim of the study was to 
investigate the role of OR stimulation in an experimental model of mild mesenteric 
ischemia developed in mice by reversible occlusion of the superior mesenteric artery 
(SMA) for 45 min followed by 5 hours of reperfusion
26, 28, 31, 44, 96
. 
In order to test our hypotesis we evalueted the effect of exogenous administration of 
a selective µOR agonist (DAMGO) in presence or absence of a µOR antagonist (CTAP) 
on the intestinal injury induced by ischemia and reperfusion in mice.  As index of local 
intestinal damage, we assessed changes in intestinal myeloperoxidase activity, mucosal 
histological integrity and ilea mRNA expression levels of interleukins (TNF-, IL-1, 
IL-10) involved in the inflammatory response.  We evaluated the alterations of 
gastrointestinal motility, to test the integrity of gastrointestinal functionality and, finally, 
we checked if I/R insult induce any variation in OR mRNA expression.  We pondered 
results obtained for I/R mice treated with OR agonist, antagonist or both, in 
comparison with I/R untreated or sham operated mice. 
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Figure 11: Molecular structure of the OR selective agonist DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-
enkephalin) and OR selective antagonist CTAP (H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2). 
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MATERIALS AND METHODS 
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Animal care and procedures were in accordance with the National Institute of Health 
recommendations for the humane use of animals.  All experimental procedures were 
reviewed and approved by Animal Research Committee of the University of California, 
Los Angeles.  Experiments were performed on female adult C57BL/6 mice (20-25g; 
Charles River Laboratories, Montreal, QC, Canada) that were housed under standard 
conditions and fasted, with free access to water, 12 hours before the experimental 
procedures. 
 
Ischemia/reperfusion and experimental design 
The study was performed using a model of mild mesenteric ischemia in mice 
previously set up by our group
96
.  Animals were anaesthetized with intra-peritoneal 
injection of Nembutal  (pentobarbital) at the dosage of 50 mg/kg. 
 
 
  
Figure 12: Anatomic localization of Superior Mesenteric Artery in mice. 
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Following abdominal laparotomy the small bowel was retracted to the left and the 
superior mesenteric artery (SMA) was identified and temporary occluded using a micro-
vascular clip for 45 min.  Then, by gently removing the clip, the reperfusion was 
allowed for a period of 5 hours and the abdominal cavity was closed by a two-layer 
suture.  Monitoring of the bloodstream showed that the SMA occlusion generate a drop 
in arterial flow, which was completely reversed by removing the clips. 
 
 
Figure 13: Doppler chart of small intestine bloodstream recorded continuously starting 10 min before the 
ischemia and ending after 10 min of reperfusion.  Note the reduction of blood flow during ischemic 
period and the return of blood flow to normal values at the end of the reperfusion. 
 
Three groups of 30-35 animals were investigated: 
1. I/R group: mice underwent 45 minutes of intestinal ischemia followed by 5 
hours of reperfusion; 
2. SO group: mice underwent sham operation (same surgical procedure and 
intestinal manipulation of I/R group, without SMA occlusion); 
3. N group: normal mice, which did not undergo any type of surgery. 
49 
 
Each group was randomly subdivided in four subgroups, each receiving one of the 
following subcutaneous treatments: 
I. Peripheral selective OR agonist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin 
(DAMGO) injected subcutaneously at the dosage of 0.01 mg/kg, 20 min 
before the ischemic period and 2h after reperfusion starts. 
 
 
II. Peripheral selective OR antagonist [H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-
Thr-NH2] (CTAP) administered subcutaneously at the dosage of 0.1 mg/kg, 
35 min before beginning of ischemia. 
 
 
III. Co-administration of DAMGO (0.01mg/kg s.c.) and CTAP (0.1 mg/kg s.c.) 
according with the previous scheduled time. 
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IV. Subcutaneously injection of the vehicle used for peptides administration: 
saline solution (NaCl 0.9%, 1ml/kg) 20 min before the beginning of ischemic 
period. 
 
 
Dosages and administration schedules of OR agonist and antagonist were choose 
based both on scientific literature reported data
95
 supported by a pilot study (DAMGO 
0.01, 0.01 and 0.001 mg/kg; CTAP 0.1 and 0.01mk/kg), as well as considering 
elimination half-lives of the peptides (DAMGO: t1/2=15 min
97
; CTAP: t1/2>8 hours
98
). 
At the end of the experiments mice were euthanized with isofluorane followed by 
thoracotomy.  Specimens of the ileum were immediately collected and processed for 
histological and biochemical analysis. 
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Intestinal histology 
Specimens of the distal ileum were collected from the different groups of animals to 
determine the level of mucosal damage.  Following overnight fixation in 10% formalin, 
samples of ileum were embedded in paraffin.  Sections (4 m thickness) were stained 
with hematoxylin and eosin. 
Microscopic histological damage score was evaluated by a person unaware of the 
treatments and was based on a semi-quantitative scoring system
99
 in which the 
following features were graded: 
 epithelium damage: 0 morphologically normal; 1 development of sub-epithelial 
space; 2 sub-epithelial space with moderate lifting of epithelial layer; 3 severe 
epithelial lifting. 
 inflammatory cells infiltration: 0 absence of infiltrate or less than five cells; 1 
mild infiltration to the lamina propria; 2 moderate infiltration to the muscularis 
mucosa and submucosa; 3 severe transmural infiltration involving the muscle 
layer. 
 extent of muscle thickening: 0 normal; 1 moderate; 2 severe. 
 edema: 0 no edema; 1 zone edema in lamina propria and submucosa; 2 diffuse 
edema in lamina propria and submucosa. 
 apoptotic cells in crypts: 0 no or less than five apoptotic cells; 1 few apoptotic 
cells on some crypts; 2 diffuse apoptotic cells on crypts throughout the whole 
cross-section. 
Data were expressed as sum of scores for each feature (total score). 
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Gastrointestinal motility 
Gastrointestinal (GI) transit was measured by evaluating the distribution of          
non-absorbable fluorescent 70,000MW dextran (150l, 5mg/ml), administered 
intragastrically by gavages 90 minutes before the euthanasia of animals. 
 
 
 
The entire GI tract, from stomach to distal colon, was excised and divided into 15 
segments: stomach, small intestine (10 segments of equal length), cecum and colon (3 
segments of equal length).  The luminal content of each segment was collected, 
suspended in 1ml of distilled water, mixed vigorously and clarified by centrifugation 
(15min at 14,000rpm at 4C).  The supernatants of each sample were collected and the 
fluorescence signal was determined in triplicates by using a fluorescence plate reader 
(excitation wavelength 485nm and emission wavelength 528nm, FLX800 Microplate 
Fluorescence Reader, Bio-Tek instruments Inc., Winooski, VT, USA). 
GI transit was calculated as the geometric centre (GC) of the distribution of labeled 
dextran along the entire gastrointestinal tract
100
. 
 
GC =  (% 𝑜𝑓 𝑓𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑝𝑒𝑟 𝑠𝑒𝑔𝑚𝑒𝑛𝑡)  × (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑔𝑚𝑒𝑛𝑡) 
 
GC value ranges from 1 (all the fluorescent dextran stays in the stomach, index of 
block in GI motility) to 15 (100% of the fluorescent signal measured in distal colon).  
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Myeloperoxidase activity 
Myeloperoxidase (MPO) activity, an index of tissue neutrophil accumulation, was 
measured according to Krawisz‟s modified method101. 
Intestinal samples were homogenized (1:10, v/v) in a solution containing aprotinin 
1g/ml in 100mM potassium phosphate buffer (pH 7.4) and centrifuged for 25min at 
10,000rpm at 4C.  Pellets were re-homogenized (1:5, v/v) in 50mM potassium 
phosphate buffer (pH 6) containing 0.5% hexadecylthrimethyl-ammonium bromide 
(HTAB) and aprotinin 1g/ml.  Samples were divided into two aliquots, subjected to 
three cycles of freezing (15min, -80C) and thawing (20min, 37C), and then 
centrifuged for 30min at 12,000rpm at 4C.  An aliquot of the supernatant (100l) was 
allowed to react with a buffer solution of -dianisidine (0.167mg/ml) and 0.0005% 
H2O2.  The rate of change in absorbance was measured with a spectrophotometer at 
470nm (Du 530, Beckman Coulter, Fullerton, CA, USA). 
One unit of MPO was defined as the quantity of enzyme degrading 1 mmol of 
peroxide per minute at 25C.  Data were expressed in mU/mg of wet tissue. 
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Cytokines and OR mRNA expression in the ileum 
 
Total RNA extraction 
Samples of ileum were homogenized with Power Gen 125 (Fischer scientific, 
Pittsburgh, PA, USA) and total RNA was extracted using the Absolutely RNA

 RT-
PCR Miniprep Kit (Stratagene, La Jolla, CA, USA).  The quality of RNA was verified 
by electrophoresis on a 2% agarose gel and the amount of the purified RNA was 
determined by spectrophotometry (Nanodrop 1000, Thermo Scientific, Waltham, MA, 
USA).  Spectrophotometric analysis of the samples showed absorption (OD) ratio 
OD260nm/OD280nm>1.9, indicating excellent purity of the ribonucleic acids. 
Total RNA (1 g) was reverse transcribed using SuperScript III First-Strand 
Synthesis System for RT-PCR (Invitrogen Corp., Carlsbad, CA, USA). 
Real-time quantitative RT-PCR 
The expression of OR, pro-inflammatory cytokine TNF- and interleukins 1 and 
10 (IL-1 and IL-10) mRNA were assessed using quantitative real time reverse 
transcription-polymerase chain reaction (RT-PCR).  Pre-designed mice TaqMan probes 
were used to quantify OR, TNF-IL-1 and IL-10 gene expression (TaqMan Gene 
Expression Assays, Applied Biosystem, Carlsbad, CA, USA).  The PCR reaction 
mixture was incubated at 95C for 10 min and then run for 50 cycles at 95C for 15 sec 
and 60 C for 1 min using Stratagene Mx 3000p machine.  Expression of -actin 
(an endogenous internal control gene) was measured in parallel for every sample and 
the data obtained for OR, TNF-and interleukins were normalized to those of the -
actin.  Relative quantities (RQ) of mRNA were analyzed using the comparative 
threshold cycle (CT) method
102, 103
. 
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Drugs 
DAMGO ([D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin), CTAP ([H-D-Phe-Cys-Tyr-
D-Trp-Arg-Thr-Pen-Thr-NH2]), -dianisidine, HTAB, aprotinin were obtained from 
Sigma Aldrich Corporation (St. Louis, MO, USA).  Myeloperoxidase was purchased 
from Calbiochem-EDM Chemicals, (La Jolla, CA, USA). 
 
Statistic analysis 
Data are expressed as means ±SEM.  Comparison among groups was made using 
analysis of variance (two-way ANOVA) followed by Bonferroni‟s post-test.  
Differences were considered significant when P value was below 0.05.  Analysis was 
performed using Prism 4 program (GraphPad Software, San Diego, CA). 
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RESULTS 
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Intestinal histology 
Sham operation induced edema and slight epithelial lifting compared to N mice.  
Among saline treated animals, an increase in the histological damage of I/R mice 
compared to SO and N was observed for each parameter considered and the total score 
was significantly increased (I/R = 8.43±0.57; SO = 3.14±0.91; N = 1.25±0.25; 
p<0.001).  Intestinal I/R induced pronounced neutrophil infiltration within lamina 
propria and submucosa, edema, lifting of the epithelial layer from lamina propria, 
apoptosis in crypts cells and muscle thickening. 
Treatment with the selective OR agonist peptide DAMGO, significantly reduced 
histological ileal damage in I/R mice by lowering edema, epithelial lifting, number of 
apoptotic cells in crypts and infiltration of inflammatory cells in intestinal tissue (total 
score I/R treated with DAMGO = 5.6±0.6, p<0.01).  This effect was completely 
reversed by the co-administration of the OR antagonist peptide, CTAP (total score = 
9.0±0.45, p<0.001).  Treatment with OR agonist or antagonist did not affect the 
histological appearance in the SO and N groups compared to vehicle treated animals. 
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Graph 1: Histological damage.  Representative histological section of mice ileum from normal 
[A], and ischemic/reperfused [B] animals.  I/R induced marked neutrophil infiltration, edema, 
epithelial lifting, apoptosis in cells in the crypts and muscle thickening.  DAMGO significantly 
reduced histological damage in I/R mice [C] (p<0.01), effect that was reversed by co-
administration of CTAP.  Levels of tissue damage were evaluated using a semi-quantitative 
scoring system; final data are summarized in the histogram.  All values are reported as mean 
±SE of 6-7 animals. **p<0.01, *** p<0.001 (two-way ANOVA followed by Bonferroni‟s post-
test). 
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Gastrointestinal transit 
A significant delay in GI transit was observable both in I/R (geometric centre GC = 
3.27±0.27) and in SO (GC = 4.93±0.58) groups compared to N (GC = 7.76±0.50) 
(p<0.001).  There is slightly delay in GI transit between I/R an SO animals, however not 
statistically different.  GI transit in I/R, SO or N was not affected by administration of 
DAMGO (GC = 4.14±0.43 in I/R group; 4.61±0.55 in SO group; 7.79±0.33 in N group) 
or CTAP (GC = 4.01±0.36 in I/R group; 4.58±0.66 in SO group; 8.81±0.73 in N group). 
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Graph 2: Effect on gastrointestinal motility in ischemic-reperfused, sham operated and normal 
mice with different treatments: saline solution (1ml/kg), DAMGO (0.01mg/kg), 
DAMGO+CTAP (0.1mg/kg) or CTAP alone.  All values are reported as mean ±SEM of 6-10 
animals.  *** p<0.001 (two-way ANOVA followed by Bonferroni‟s post-test). 
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Myeloperoxidase activity 
MPO activity in tissue homogenates was measured to assess the extent of neutrophils 
recruitment.  I/R induced a 5-fold increase in intestinal MPO activity (p<0.05), 
compared to the SO and N animals (I/R = 0.85±0.13; SO = 0.17±0.03 and N = 
0.14±0.03 mU/mg of wet tissue).  DAMGO treatment resulted in a pronounced and 
significant reduction of MPO levels in I/R mice compared to saline (I/R = 0.29±0.07, 
p<0.05).  DAMGO effect was completely reversed by simultaneous treatment with 
CTAP (I/R = 1.62±0.45, p<0.001), confirming that it was a receptor-mediated effect.  
CTAP alone induced a slight, but not significant, increase of MPO activity in I/R 
compared to I/R group treated with saline (I/R = 1.38±0.34) and a weak increase in SO 
mice compared to SO treated with saline (SO = 0.41±0.16).  DAMGO or CTAP 
administration did not affect MPO activity in N mice. 
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Graph 3: MPO activity, index of neutrophil accumulation in intestinal tissue, in ischemic-
reperfused, sham operated and normal mice treated with: saline solution (1ml/kg), DAMGO 
(0.01mg/kg), DAMGO+CTAP (0.1mg/kg) or CTAP alone.  All values are reported as mean 
±SE of 6-10 animals. * p<0.05, *** p<0.001 (two-way ANOVA followed by Bonferroni‟s 
post-test). 
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Cytokines mRNA expression 
Interleukin-1(IL-1) 
IL-1 is a cytokine released from macrophages able to promote the inflammatory 
response, increasing endothelial leukocyte adhesion and phagocyte activation
104
. 
The mRNA levels of IL-1 quantified in ileum tissue of I/R (RQ_folds = 2.36±0.44) 
and SO (2.47±0.46) mice were little higher compared to N (1.10±0.17) animals, 
however there were no significant differences in tissue expression of this cytokine. 
Tumor Necrosis Factor-TNF 
TNF- is a pro-inflammatory cytokine, released from macrophages, monocytes, 
lymphocytes and other cells, capable of increasing other cytokines release in the 
inflammatory cascade as well as eliciting leukocyte migration
104
. 
The levels of TNF- mRNA expression quantified by real time PCR were 
significantly higher in I/R animals compared to SO and N mice (RQ_folds I/R = 
4.34±0.67, SO = 1.66±0.33 and N = 1.12±0.26; p<0.05).  Treatment with DAMGO 
inhibited the production of TNF- mRNA in I/R mice (I/R = 1.95±0.40; p<0.05) and 
this effect was abolished by the co-administration of CTAP (I/R = 3.42±0.96).  CTAP 
alone did not modify the expression of TNF- mRNA in I/R mice but significantly 
increased it in SO (SO = 5.25±1.04; p<0.05), suggesting the occurrence of endogenous 
stimulation of ORs in the modulation of this cytokine pathway during surgery 
manipulation.  TNF- mRNA in N mice was not altered by DAMGO or CTAP 
administration. 
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Graph 4: Quantification of TNF- mRNA concentrations in intestinal tissue of ischemic-
reperfused, sham operated and normal mice treated with: vehicle (saline solution, 1ml/kg), 
DAMGO (0.01mg/kg), DAMGO+CTAP (0.1mg/kg) or CTAP alone.  All values are reported 
as mean ±SE of 8-10 animals. * p<0.05 (two-way ANOVA followed by Bonferroni‟s post-
test). 
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Interleukine-10(IL-10) 
IL-10 is a counter regulatory cytokine produced by T-helper2 cells, implicated as an 
inhibitor of pro-inflammatory cytokine production and of several accessory cell 
functions of the macrophage, T-cells and NK cell lines
104
. 
IL-10 mRNA expression was significantly higher in I/R mice (RQ_folds = 
4.57±0.64) compared to SO (1.79±0.42; p<0.05) and N animals (1.14±0.23; p<0.05).  
However, the treatment with DAMGO did not alter the expression of this cytokine (I/R 
= 5.63±1.31, SO = 0.96±0.14, N = 1.27±0.2). 
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Graph 5: Quantification of IL-10 mRNA concentrations in intestinal tissue of ischemic-
reperfused, sham operated and normal mice treated with: vehicle (saline solution, 1ml/kg) and 
DAMGO (0.01mg/kg).  All values are reported as mean ±SE of 8-10 animals.  * p<0.05, ** 
p<0.01, *** p<0.001(two-way ANOVA followed by Bonferroni‟s post-test). 
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OR mRNA levels 
Recent evidence showed that intestinal inflammation induces an increment in OR 
expression.  In our experimental model and conditions, we did not observe significant 
differences in OR mRNA levels in the ileum samples of I/R, SO and N mice. 
(RQ_fold 1.63±0.28 in I/R group; 1.47±0.25 in SO group; 1.19±0.22 in N group). 
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Graph 6: Quantification of OR mRNA expression in intestinal tissue of ischemic-reperfused, 
sham operated and normal mice treated with vehicle (saline solution, 1ml/kg).  All values are 
reported as mean ±SE of 8-10 animals. There are no significant differences between the 
groups. 
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DISCUSSION 
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An experimental model of mesenteric ischemia and reperfusion in rats and mice was 
previously set up by our group
28, 44, 96
.  In this model, occlusion of the superior 
mesenteric artery (SMA), through microvascular clips or nylon threads, was performed 
for 45 minutes and followed by 24 hours of reperfusion.  These experimental conditions 
were associated to a mild intestinal inflammation and reversible changes in enteric 
motility
96
.  During reperfusion, PMNs are activated and start to infiltrate into the bowel 
wall, contributing to the tissue injury typical of acute inflammatory response
105
.  In this 
new investigation we choose a reperfusion time of 5 hours based on previous studies 
showing that the maximal systemic activation of neutrophils occurs within 4-5 hours of 
reperfusion
106
.  In this experimental conditions (I45ʹ/R5h) animals underwent ischemia 
and reperfusion showed increased mucosal damage characterized by pronounced 
neutrophil infiltration within lamina propria and submucosa, edema, lifting of the 
epithelial layer from lamina propria, apoptosis in crypts cells and muscle thickening.  
Neutrophils infiltration in intestinal tissue was supported also by the increase of MPO 
activity measured in ileal homogenates.  Moreover, the presence of inflammation was 
confirmed by the augmented expression of pro-inflammatory cytokines (TNF-, IL-1, 
IL-10) mRNA in I/R mice; while a delay in the gastrointestinal transit was detected as 
index of impaired gastrointestinal motility. 
Derangement of functional communication between enteric nerves with hormones 
and neuropeptides, like opioid peptides, has been shown to play a major role in the 
pathophysiology of Inflammatory Bowel Diseases (IBD)
107
; and it is demonstrated that 
exogenous specific activation of µOR exerts a protective effect controlling 
inflammation induced by experimental colitis in rodents, even if the exact mechanism 
underlying is not completely clarified
94, 95
.  This study displays that the exogenous 
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activation of ORs, through the selective agonist DAMGO, prevents intestinal injuries 
associated with mesenteric I/R in mice.  Indeed, DAMGO treatment ameliorates 
histological damage of the mucosa by reducing inflammatory cells infiltration within 
lamina propria and submucosa, edema, epithelial lifting, presence of apoptotic cells in 
crypts and muscle thickening in I/R mice.  It is demonstrated that intestinal I/R is 
associated with the early recruitment of CD4+ and CD8+ T-cells and T-cells seem to 
modulate the infiltration of neutrophils that occurs hours after the inception of 
reperfusion
8, 23
.  This study shows that DAMGO administration was able to reduce the 
inflammatory response caused by mesenteric I/R and that ORs activation strongly 
decreases neutrophil accumulation in intestinal tissue, as attested from the drop in MPO 
activity compared to untreated I/R mice. 
In order to understand the underneath mechanism of OR protective effect we 
analyzed the intestinal expression of different cytokines.  TNF- is a pro-inflammatory 
cytokine, released from macrophages, monocytes, lymphocytes and other cells, capable 
of increasing other cytokines release in the inflammatory cascade as well as eliciting 
leukocyte migration
104
.  An increase of the pro-inflammatory cytokine TNF- levels 
has been reported during the ischemic period and the early reperfusion in mice
108 
and 
our data, in accordance, demonstrate that after 5 hours of reperfusion, TNF- levels are 
significantly augmented in post ischemic intestinal tissues and give evidence that 
mRNA expression of TNF-is reduced after ORs activation with DAMGO.  
Interleukin 1 (IL-1 is a cytokine released from macrophages that promotes the 
inflammatory response, increases endothelial leukocyte adhesion and phagocyte 
activation
104
.  The levels of IL-1expression in the ileum of I/R and SO mice were 
lightly increased compared to N animals, however there was no significant difference 
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between ischemic and sham operated animals.  On the other hand, we analyzed the 
expression of interleukin 10 (IL-10), a counter regulatory cytokine produced by T-
helper2 cells, implicated as an inhibitor of pro-inflammatory cytokines production and 
of several accessory cell functions of the macrophage, T-cells and NK cell lines
104
.  Our 
data showed that IL-10 mRNA expression was significantly higher in I/R mice 
compared to SO and N; however, treatment with DAMGO did not modify this 
expression pattern.  Based on these findings we suggest that the anti-inflammatory role 
of OR is likely correlated with regulation of cytokines expression, such as TNF-, and 
the consequent modulation of inflammatory cells recruitment. 
In order to assess if DAMGO protective effects on histological damage score, MPO 
activity and TNF- mRNA expression were ORs mediated, we repeated the 
experiment treating the animals with DAMGO in presence of the selective OR 
antagonist CTAP.  Data obtained showed that beneficial effects of DAMGO, on each 
inflammatory index checked, were abolished by simultaneous administration of the 
selective OR antagonist CTAP; confirming that they were ORs mediated. 
Previous study showed that OR mRNA expression is increased in inflammatory 
bowel disease in humans and in experimental TNBS-induced colitis in mice
95
 and in a 
model of croton-oil induced intestinal inflammation
93
.  Our results did not display any 
increase in the mRNA receptor expression.  A possible explanation for these data could 
be associated with the relatively short time (5 hours) that occurs between the I/R injury 
and the euthanasia of the mice.  It is likely that a chronic inflammation or a more severe 
and persistent mucosal damage are necessary to activate intracellular pathways able to 
increase OR gene transcription. 
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It is well know that opioid peptides have a physiological role in the control of gut 
motility and that opiate ORs stimulation induces a delay in gastrointestinal transit.  In 
this study administration of DAMGO did not modify the GI transit that appeared 
reduced in I/R and SO compared to N mice.  The inability to reveal DAMGO effect on 
GI transit, even in N animals, is probably due to the length of the interval of time that 
elapses between DAMGO administration and GI transit measurement performed in this 
study (about 3 hours).  The short half life of DAMGO (t1/2 = 15 min) accounts for the 
repeated DAMGO administration we adopted in this study and leads us to interpret 
DAMGO effects, when present, as indirect rather than direct responses.  Reasonably 
DAMGO effects are consequence of interference with the processes operating during 
ischemia and reperfusion rather than the direct presence of the agonist at the moment of 
parameter measurement.  In fact, previous studies on rats showed that the inhibition of 
GI transit can be appreciated only within 25 minutes from DAMGO systemic 
administration
109
.  On the other hand, the absence of any effect of the OR antagonist 
CTAP treatment on motor activity in each experimental group suggests a negligible 
involvement of endogenous opioid system in the GI transit delay observed in SO and 
I/R mice. 
Opiate-mediated immunomodulatory effects have been postulated to result from 
direct activation of opioid receptors on cells of the immune system or indirectly, 
through the activation of opioid receptors within the central nervous system and the 
resulting modulation of hypothalamic pituitary adrenal axis and the sympathetic 
nervous system
67
.  Both DAMGO and CTAP are not able to cross the blood-brain 
barrier suggesting that anti-inflammatory properties shown in this experimental model 
are correlated to the activation of peripheral OR and are not related to stimulation of 
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central receptors.  These findings support the hypothesis that peripheral OR agonists 
could have therapeutic anti-inflammatory effects in intestinal ischemia, without 
appearance of unwanted central adverse effects (e.g. respiratory depression, euphoria, 
somnolence, sedation and addiction)
110
.  Furthermore the participation of the 
endogenous opioid system and its relevance in the modulation of the immuno-response 
activated by intestine manipulation is supported by the significant increase of TNF- 
mRNA levels observed after CTAP treatment in SO mice.  The absence of such effect in 
I/R mice could simply derive from the simultaneous activation of other additional 
biochemical pathways, that cooperate along the opioid system, in the physiological 
counter-regulation of the more sustained acute inflammatory response elicited by 
ischemia and reperfusion.  In this context opioid system can be seen as an early 
endogenous regulator involved in the pro-resolving mechanism aimed at blunting the 
TNF- production, whose increase is the initial sub-clinical response to manipulation of 
the intestine. 
In summary, this investigation shows that exogenous activation of ORs plays a 
protective role in our experimental model of mesenteric ischemia-reperfusion in mice.  
Indeed, OR activation is able to reduce the intestinal damage induced by ischemia and 
reperfusion, through a mechanism that appears to be in part mediated by TNF-.  This 
suggests that peripheral µOR agonists might be potential therapeutic approaches for I/R-
induced inflammatory injury. 
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